Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 11


Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.

Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA.

Cancer. 2010 Mar 15;116(6):1582-91. doi: 10.1002/cncr.24927.


Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR.

Clin Cancer Res. 2009 Oct 1;15(19):6232-40. doi: 10.1158/1078-0432.CCR-09-0224. Epub 2009 Sep 29.


MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature.

Bolch WE, Eckerman KF, Sgouros G, Thomas SR.

J Nucl Med. 2009 Mar;50(3):477-84. doi: 10.2967/jnumed.108.056036.


Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL.

Clin Cancer Res. 2008 Jun 15;14(12):3881-8. doi: 10.1158/1078-0432.CCR-07-5095.


Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics.

Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D.

Drug Metab Dispos. 2008 Sep;36(9):1828-39. doi: 10.1124/dmd.107.020255. Epub 2008 Jun 12.


Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.

J Med Chem. 2007 Nov 15;50(23):5853-7. Epub 2007 Oct 23.


"Getting the dose right": facts, a blueprint, and encouragements.

Peck CC, Cross JT.

Clin Pharmacol Ther. 2007 Jul;82(1):12-4. No abstract available.


Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C, Castaneda S, Inigo I, Kan D, Wen ML, Kramer R, Blackwood-Chirchir A, Lee FY.

Clin Cancer Res. 2006 Dec 1;12(23):7180-6.


Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J; Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee.

J Natl Cancer Inst. 2006 May 3;98(9):580-98. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk